Always glad to admit my suspicions were wrong - based on @CIBMTR data, no reason to doubt ide-cel CAR-T’s efficacy in #MMsm based on presence vs absence of prior transplant. Now in @BloodPortfolio - by @drjgauthier @emilyliangmd @MadhavDhodapkar @AJPortuguese @fredhutch et al!

Here are the top clinically relevant #ASH25 abstracts in plasma cell disorders that caught my attention. This thread is for abstracts in the newly diagnosed myeloma space:

3. LimiTec Trial: Prospective study of Tec discontinuation after 6-9 months of therapy in patients achieving >=VGPR (BMBx/MRD assessment not required): n=43 with 4 prior LoT, 95% TCR, 44% penta-refractory, 23% with prior BCMA-DT. Median f/u ~11 months. Failure-Free Probability

Agree. I will also add that autologous transplants are wayyyy safer than currently available CAR-T constructs with a predictable side effect profile . That might change with future CAR-T constructs but until then autologous transplants can safely improve PFS and help delay CAR-T

I am glad this myth has been dispelled. Our data set shows similar lack of impact based on transplant. It boils down to choosing treatments at each phase the prolong pfs the most. Among newly diagnosed patients pfs is significantly longer with early transplant.

🧵1/ A single-center report suggested prior ASCT may worsen ide-cel outcomes in RRMM. We tested this in a much larger cohort: 805 U.S. pts s/p ide-cel in the @CIBMTR registry. @RahulBanerjeeMD @drjgauthier @emilyliangmd @fredhutch 🚨 @BloodPortfolio:

For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology. https://t.co/aV2rpKDtgI @AlGarfall

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd - Update: 11/13/25 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @szusmani

#mmsm

Data on more pts and longer f/u at the meeting (poster 4099, Mon evening). Study led by @BeaRazzo in collaboration with Drs. @rajshekharucms @hiragss and Carolina Schinke and with support from @BloodCancerUtd

Key findings: - N=43, 23% with prior BCMA tx, median f/u 10.6m - 12m after stopping tec, 73% remain progression-free, similar to outcomes with continuous tec - Early PD pts were BCMA-neg and responded to talquetamab, suggesting PD was not due to stopping tec

Thanks to several #mmsm folks who have highlighted our #ASH25 abstract reporting preliminary results from our LimiTec trial, which prospectively evaluates discontinuation of teclistamab in patients with ≥VGPR after 6-9 months. https://t.co/wNGiWEBask

My top 8 myeloma/amyloidosis #ASH25 abstracts @ASH_hematology #mmsm 8⃣LimiTec: Limited Duration Teclistamab (Abstract #292744 - Razzo et al. @AlGarfall ) ➡️Can we stop bispecifics after deep response? Early data says YES! ➡️6-mo FFP: 77%, 12-mo FFP: 73% ➡️Similar outcomes in

Check our recent multi-institutional real world data on the use of Talquetamab in myeloma #mmsm @BloodCancerJnl ✅114 RRMM pts (median 6 prior lines, 100% triple-class refractory, 79% penta-refractory, 65% prior BCMA therapy) ✅ORR 73% (26% CR, 26% VGPR), median PFS 10 months

2- Creative approaches - Ultra HR MM: UKMRA RADAR https://t.co/QRZtOgOQPa - Limited duration bispecifics LimiTec https://t.co/CzF8UuB626 Fitfix https://t.co/UmURtji5Xm - Point-of-care CAR https://t.co/OI7bginhKE - At-home tx delivery https://t.co/WVScOJ3Wea #ASH25 #mmsm

#Myeloma Paper of the Day: Study of outcomes of relapse after teclistamab finds 1-year OS & PFS from start of 1st salvage of 57% (95% CI: 44.9–72.4) & 17.5% (95% CI: 10.2–30.2), & median OS & PFS of 14.6 (95% CI: 8.3–NE) & 2.8 (95% CI: 1.9–4.3) mos: https://t.co/c7zkaaU0DL. #mmsm

🚨 @columbiacancer Now enrolling (and soon @BU_Amyloidosis and @MedicalCollege): First prospective trial testing fixed-duration BCMA-directed therapy (teclistamab) + daratumumab in newly diagnosed AL amyloidosis! Given impressive depth/speed of responses with BCMA BsAbs in R/R

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

It was really fun talking with these guys! Great discussion after the IMS meeting about bispecifics and more.

Great job leading this one @RahulBanerjeeMD D30 ALC is a significant predictor of delayed responses to Tec in RRMM for initial non-responders. American Journal of Hematology | https://t.co/RT7oxhYR07 @GKaurMD @AlGarfall @SurbhiSidanaMD @utswcancer